# DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer

> **NCT02838225** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel, Doxorubicin
- **DRUG:** Docetaxel, Doxorubicin, Cyclophosphamide

## Key facts

- **NCT ID:** NCT02838225
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2016-01
- **Final completion:** —
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02838225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02838225, "DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02838225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*